Extremely low 90-day cardiac device infection rates with TYRX antibacterial envelope use

Use of TYRX, Inc.'s AIGISRx® Antibacterial Envelope reduced major infection rates over 90 percent in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacements compared to similar high-risk cohorts, according to CITADEL & CENTURION study results. CITADEL / CENTURION is a prospective, 55-center clinical study to evaluate major device infection and mechanical complication rates in the 12 months after implantation, in patients at high risk for CIED infection whose CIED was...

Fuente : http://www.eurekalert.org/pub_releases/2013-05/ka-...